Targeting cancer proteins for degradation

February 24, 2016, Friedrich Miescher Institute for Biomedical Research
Targeting cancer proteins for degradation

Cancer research is increasingly focusing on therapeutic approaches in which disease causing proteins are marked for early degradation. Nicolas Thomä and his group at the Friedrich Miescher Institute for Biomedical Research have now shown how pharmaceutical compounds hijack an ubiquitin ligase to target such proteins for degradation. This new mechanism could provide opportunities for targeted degradation of cancer proteins.

During the last decade, cancer researchers have been seeking to exploit the cellular "waste disposal system" to induce of proteins that cause or promote cancer. To trigger degradation, cellular proteins need to be labeled with a disposal tag, which is achieved by the activity of so called enzymes. Therefore, researchers have pursued various strategies for rendering disease-causing proteins susceptible to the action of ubiquitin ligases and thus inducing degradation.

In a study published today in Nature, Nicolas Thomä, a group leader at the Friedrich Miescher Institute for Biomedical Research (FMI), and co-workers have now shown that small pharmaceutical molecules (compounds) destabilize specific cancer proteins by gluing them to an ubiquitin ligase. Thomä comments: "This is a new mode of action for a therapeutic agent, as it induces selective degradation of specific targets rather than inhibiting enzymatic function. It also represents a new emerging paradigm in pharmacology, and we now see for the first time how this works on the molecular level."

The scientists described this new mechanism by investigating the thalidomide derivative lenalidomide. This drug is clinically effective in the treatment of blood cancers such as multiple myeloma and myelodysplastic syndrome, where it induces degradation of various cancer-associated proteins, including casein kinase 1α (CK1α). However, it remained unclear how lenalidomide alters the specificity of the relevant ubiquitin ligase complex so that CK1α is marked for degradation.

By elucidating the crystal structure of DDB1–CRBN bound to lenalidomide and CK1α, first author Georg Petzold (a postdoc in Thomä's group) showed that lenalidomide enables the binding of CK1α. Petzold explains: "In the ubiquitin ligase complex, CRBN is responsible for recruiting substrates. We found that lenalidomide binding to CRBN creates a neomorphic interface that is necessary to bind CK1α."

In the case of lenalidomide, the efficacy of the drug is based on inducing the destruction of disease causing enzymes rather than inhibiting its . Thomä says: "By observing how a small molecule glues a to an ubiquitin ligase, we now have a blueprint that will help develop new small molecule therapeutics that work by a related mechanism and could be applied to other diseases."

Explore further: Mechanism of action of thalidomide elucidated

More information: Petzold G, Fischer ES, Thomä NH (2016) Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase. Nature [Epub ahead of print]

Related Stories

Mechanism of action of thalidomide elucidated

July 17, 2014
(Medical Xpress)—Scientists led by Nicolas Thomä at the Friedrich Miescher Institute for Biomedical Research have clarified the workings of thalidomide at the molecular level. Their analysis of various structures, published ...

Study reveals how lenalidomide fights cancer and treats blood syndrome

July 2, 2015
(Medical Xpress)—A team of researchers with member affiliations to institutions in the U.S. and Germany has uncovered the mechanism by which a cancer fighting drug reduces cancer cells and also helps patients with a blood ...

Recommended for you

Fabric imbued with optical fibers helps fight skin diseases

February 23, 2018
A team of researchers with Texinov Medical Textiles in France has announced that their PHOS-ISTOS system, called the Fluxmedicare, is on track to be made commercially available later this year. The system consists of a piece ...

Low-calorie diet enhances intestinal regeneration after injury

February 22, 2018
Dramatic calorie restriction, diets reduced by 40 percent of a normal calorie total, have long been known to extend health span, the duration of disease-free aging, in animal studies, and even to extend life span in most ...

Gut microbes protect against sepsis—mouse study

February 22, 2018
Sepsis occurs when the body's response to the spread of bacteria or toxins to the bloodstream damages tissues and organs. The fight against sepsis could get a helping hand from a surprising source: gut bacteria. Researchers ...

Artificial intelligence quickly and accurately diagnoses eye diseases and pneumonia

February 22, 2018
Using artificial intelligence and machine learning techniques, researchers at Shiley Eye Institute at UC San Diego Health and University of California San Diego School of Medicine, with colleagues in China, Germany and Texas, ...

Fertility breakthrough: New research could extend egg health with age

February 22, 2018
Women have been told for years that if they don't have children before their mid-30s, they may not be able to. But a new study from Princeton University's Coleen Murphy has identified a drug that extends egg viability in ...

Breakthrough could lead to better drugs to tackle diabetes and obesity

February 22, 2018
Breakthrough research at Monash University has shown how different areas of major diabetes and obesity drug targets can be 'activated', guiding future drug development and better treatment of diseases.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.